News & Media

Keep up to date with all of our latest news.

SparingVision to Participate in Upcoming Scientific and Medical Conferences

SparingVision to Participate in Upcoming Scientific and Medical Conferences Paris, October 25, 2022 – SparingVision…

SparingVision to Participate in Upcoming Scientific and Medical Conferences

SparingVision to Participate in Upcoming Scientific and Medical Conferences Paris, October 25, 2022 – SparingVision…

SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022

SparingVision Presents Validating Data of its Lead Gene Therapy Programs, SPVN06 and SPVN20, at ESGCT 2022…

SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20 at ESGCT Congress

SparingVision to Highlight Progress of its lead Gene Independent Gene Therapy Programs SPVN06 and SPVN20…

SparingVision SparingVision to Participate in Upcoming Investor and Industry Conferences

SparingVision to Participate in Upcoming Investor and Industry Conferences Paris, September 22, 2022 – SparingVision…

SparingVision Raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for Ocular Diseases

SparingVision raises €75 Million Series B to Continue Building World-Leading Portfolio of Genomic Medicines for…

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022

SparingVision Presents Additional Data on its Breakthrough Gene Therapy Approach SPVN06 at ASGCT 2022 Data…

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022

SparingVision Presents Progress of its Lead Gene Therapy Program, SPVN06, at ARVO 2022 Paris, May…

SparingVision Announces Oral Presentation of SPVN06 Data at ASGCT 2022

SparingVision announces Oral Presentation of SPVN06 Data at ASGCT 2022 Paris, May 3, 2022 –…

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis Pigmentosa at ARVO 2022

SparingVision to Highlight Progress of its Lead Gene Therapy Program SPVN06 and Research on Retinitis…

SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference

SparingVision to Present at the 40th Annual J.P. Morgan Healthcare Conference Paris, January 6…

News & Media Menu

LATEST TWEETS

SparingVision Follow

Genomic medicine company developing vision-saving treatments for ocular diseases #vision #blindness #genetherapy #biotech #healthtech

SparingVision @sparingvision ·

24 Nov

Our CEO @BoisselStephane explains in @BioCentury why small #biotechs need to start thinking like big companies much earlier in their lifecycle.

Read here: https://www.biocentury.com/article/645948

#GenomicMedicines #Ophthalmology #GeneTherapy #GenomeEditing

Reply on Twitter 1595739342269566976 Retweet on Twitter 1595739342269566976 Like on Twitter 1595739342269566976 2 Twitter 1595739342269566976

SparingVision @sparingvision ·

22 Nov

Last week we attended the 43rd @ACToxicology Annual Meeting in Denver, Colorado, presenting 2 posters on our lead #genetherapy asset, SPVN06, targeting Inherited #RetinalDiseases. Pictured here: Mélanie Marie, Brynne Freshour & Lucie Churet.
#Ophthalmology #ACTOX2022

Reply on Twitter 1595012409370058753 Retweet on Twitter 1595012409370058753 Like on Twitter 1595012409370058753 1 Twitter 1595012409370058753

PARTNERS

01

Home

03

Patients

02

Technologies

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.

Necessary

Always Enabled

Necessary cookies are absolutely essential for the website to function properly. These cookies ensure basic functionalities and security features of the website, anonymously.

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	6 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	6 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	6 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	6 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	6 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	Records the default button state of the corresponding category & the status of CCPA. It works only in coordination with the primary cookie.
JSESSIONID	session	The JSESSIONID cookie is used by New Relic to store a session identifier so that New Relic can monitor session counts for an application.
viewed_cookie_policy	6 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Functional

Functional cookies help to perform certain functionalities like sharing the content of the website on social media platforms, collect feedbacks, and other third-party features.

Cookie	Duration	Description
__cf_bm	30 minutes	This cookie, set by Cloudflare, is used to support Cloudflare Bot Management.

Performance

Analytics

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics the number of visitors, bounce rate, traffic source, etc.

Cookie	Duration	Description
_pk_id.1.90cf	1 year 27 days	Matamo set this cookie to store a unique user ID.
_pk_ses.1.90cf	30 minutes	This cookie is used to store a unique session ID for gathering information on how the users use the website.
vuid	6 months	Vimeo installs this cookie to collect tracking information by setting a unique ID to embed videos to the website.

Others